(Reuters) - Drug developer Arrowhead Research Corp said the U.S. Food and Drug Administration placed the company's experimental hepatitis B treatment on partial clinical hold, seeking additional data from the drug's mid-stage study.
The company's shares plunged 22 pct premarket on Monday after the FDA also asked the company to reduce the dosage of the drug, ARC-520.
21:31 Time Warner jumps after hours on report it could sell for $110 per share to AT&T6
20:52 After earning crush, Tesla expected to unveil 'solar roof', integrated home battery38
02:12 Hotly Anticipated Google Fiber High-Speed Service Put on Hold as CEO Leaves53
12:23 Lockheed Martin's quarterly profit handily beats estimates28